@article {7042,
	title = {When to recommend a second autograft in patients with relapsed myeloma?},
	journal = {Leukemia and Lymphoma},
	volume = {58},
	year = {2017},
	note = {Export Date: 18 February 2017References: Child, J.A., Morgan, G.J., Davies, F.E., High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma (2003) N Engl J Med, 348, pp. 1875-1883;Bjorkstrand, B., Gahrton, G., High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future (2007) Semin Hematol, 44, pp. 227-233; 
McElwain, T.J., Powles, R.L., High-dose intravenous melphalan for plasma-cell leukaemia and myeloma (1983) Lancet, 2, pp. 822-824; 
Harousseau, J.L., Attal, M., Divine, M., Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma (1995) Blood, 85, pp. 3077-3085; 
Attal, M., Harousseau, J.L., Stoppa, A.M., A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma (1996) N Engl J Med, 335, pp. 91-97; 
McCarthy, P.L., Owzar, K., Hofmeister, C.C., Lenalidomide after stem-cell transplantation for multiple myeloma (2012) N Engl J Med, 366, pp. 1770-1781; 
Attal, M., Lauwers-Cances, V., Marit, G., Lenalidomide maintenance after stem-cell transplantation for multiple myeloma (2012) N Engl J Med, 366, pp. 1782-1791; 
San-Miguel, J.F., Mateos, M.V., Can multiple myeloma become a curable disease? (2011) Haematologica, 96, pp. 1246-1248; 
Giralt, S., Garderet, L., Durie, B., American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma (2015) Biol Blood Marrow Transplant, 21, pp. 2039-2051; 
Attal, M., Harousseau, J.L., Facon, T., Single versus double autologous stem-cell transplantation for multiple myeloma (2003) N Engl J Med, 349, pp. 2495-2502; 
Lahuerta, J.J., Grande, C., Martinez-Lopez, J., Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espa{\~n}ol de S{\'\i}ndromes Linfoproliferativos/Trasplante Aut{\'o}logo de M{\'e}dula Osea phase II trial (2003) Br J Haematol, 120, pp. 296-303; 
Cavo, M., Tosi, P., Zamagni, E., Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study (2007) J Clin Oncol, 25, pp. 2434-2441; 
Harousseau, J.L., Avet-Loiseau, H., Attal, M., Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials (2009) J Clin Oncol, 27, pp. 5720-5726; 
Martino, M., Recchia, A.G., Fedele, R., The role of tandem stem cell transplantation for multiple myeloma patients (2016) Expert Opin Biol Ther, 16, pp. 515-534; 
Atanackovic, D., Schilling, G., Second autologous transplant as salvage therapy in multiple myeloma (2013) Br J Haematol, 163, pp. 565-572; 
Tricot, G., Jagannath, S., Vesole, D.H., Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy (1995) Bone Marrow Transplant, 16, pp. 7-11; 
Shah, N., Ahmed, F., Bashir, Q., Durable remission with salvage second autotransplants in patients with multiple myeloma (2012) Cancer, 118, pp. 3549-3555; 
Jimenez-Zepeda, V.H., Mikhael, J., Winter, A., Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival (2012) Biol Blood Marrow Transplant, 18, pp. 773-779; 
Olin, R.L., Vogl, D.T., Porter, D.L., Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma (2009) Bone Marrow Transplant, 43, pp. 417-422; 
Fenk, R., Liese, V., Neubauer, F., Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation (2011) Leuk Lymphoma, 52, pp. 1455-1462; 
Alvares, C.L., Davies, F.E., Horton, C., The role of second autografts in the management of myeloma at first relapse (2006) Haematologica, 91, pp. 141-142; 
Gonsalves, W.I., Gertz, M.A., Lacy, M.Q., Second auto-SCT for treatment of relapsed multiple myeloma (2013) Bone Marrow Transplant, 48, pp. 568-573; 
Michaelis, L.C., Saad, A., Zhong, X., Salvage second hematopoietic cell transplantation in myeloma (2013) Biol Blood Marrow Transplant, 19, pp. 760-766; 
Sellner, L., Heiss, C., Benner, A., Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients (2013) Cancer, 119, pp. 2438-2446; 
Grovdal, M., Nahi, H., Gahrton, G., Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT (2015) Bone Marrow Transplant, 50, pp. 808-812; 
Singh Abbi, K.K., Zheng, J., Devlin, S.M., Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma (2015) Biol Blood Marrow Transplant, 21, pp. 468-472; 
Auner, H.W., Szydlo, R., Rone, A., Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation (2013) Leuk Lymphoma, 54, pp. 2200-2204; 
Cook, G., Liakopoulou, E., Pearce, R., Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry (2011) Biol Blood Marrow Transplant, 17, pp. 1638-1645; 
Lemieux, E., Hulin, C., Caillot, D., Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma (2013) Biol Blood Marrow Transplant, 19, pp. 445-449; 
Blimark, C., Veskovski, L., Westin, J., Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation (2011) Eur J Haematol, 87, pp. 117-122; 
Cook, G., Ashcroft, A.J., Cairns, D.A., The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomized, open-label, phase 3 trial (2016) Lancet Haematol, 3, pp. e340-e351; 
Krivanova, A., Hajek, R., Krejci, M., Second autologous transplantation for multiple myeloma patients relapsing after the first autograft{\textendash}a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group (2004) Onkologie, 27, pp. 275-279; 
Elice, F., Raimondi, R., Tosetto, A., Prolonged overall survival with second on-demand autologous transplant in multiple myeloma (2006) Am J Hematol, 81, pp. 426-431; 
Burzynski, J.A., Toro, J.J., Patel, R.C., Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma (2009) Leuk Lymphoma, 50, pp. 1442-1447; 
Blade, J., Rosinol, L., Fernandez de Larrea, C., How I treat relapsed myeloma (2015) Blood, 125, pp. 1532-1540; 
Lee, C.K., Barlogie, B., Zangari, M., Transplantation as salvage therapy for high-risk patients with myeloma in relapse (2002) Bone Marrow Transplant, 30, pp. 873-878; 
Krejci, M., Adam, Z., Buchler, T., Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma (2010) Ann Hematol, 89, pp. 483-487; 
Gimsing, P., Hjertner, O., Abildgaard, N., Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial (2015) Bone Marrow Transplant, 50, pp. 1306-1311; 
van Rhee, F., Giralt, S., Barlogie, B., The future of autologous stem cell transplantation in myeloma (2014) Blood, 124, pp. 328-333; 
Cook, G., Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents (2015) Bone Marrow Transplant, 50, pp. 1269-1270; 
Giralt, S., Stadtmauer, E.A., Harousseau, J.L., International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) Leukemia, 23, pp. 1904-1912; 
Mehta, J., Tricot, G., Jagannath, S., Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? (1998) Bone Marrow Transplant, 21, pp. 887-892
},
	month = {2017},
	pages = {781 - 787},
	abstract = {In the current evolving landscape of myeloma therapies, no recommended salvage strategy exists for patients with relapsed multiple myeloma (MM) after initial successful autologous stem cell transplantation (ASCT) and therapeutic options extend from conventional chemotherapy and novel agents to second autologous and allogeneic transplants. In this article, we summarize the documented evidence about the utilization of second ASCT in patients with relapsed MM after a primary auto-graft and discuss the correct timing for such a salvage approach, the individual characteristics of patients who will benefit more, as well as the therapeutic role of second ASCT in the modern era of forthcoming anti-myeloma treatments. {\textcopyright} 2016 Informa UK Limited, trading as Taylor \& Francis Group.},
	keywords = {multiple myeloma, relapse, Second ASCT},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84999810220\&doi=10.1080\%2f10428194.2016.1246729\&partnerID=40\&md5=4d4675f6b9428398c6e5fdafa5dc0c3c},
	author = {Ziogas, D.C. and Terpos, E. and Dimopoulos, M.A.}
}
